Revenues - (Tables)

6 Months Ended

Jun. 30, 2020

Revenue from Contract with Customer [Abstract]

Summary of Disaggregation of Revenue

The following table presents a summary of total revenues (in thousands): 

	Three Months Ended June 30,				Six Months Ended June 30,
	2020		2019		2020		2019
Xyrem	$	446,808	$	413,212	$	854,683	$	781,529
Defitelio/defibrotide	42,714		46,055		90,146		87,555
Erwinaze/Erwinase	32,683		27,622		70,415		88,521
Vyxeos	26,568		31,362		59,288		60,305
Sunosi	8,578		—		10,502		—
Other	852		5,172		3,374		8,844
Product sales, net	558,203		523,423		1,088,408		1,026,754
Royalties and contract revenues	4,233		10,710		8,754		15,565
Total revenues	$	562,436	$	534,133	$	1,097,162	$	1,042,319

The following table presents a summary of total revenues attributed to geographic sources (in thousands): 

	Three Months Ended June 30,				Six Months Ended June 30,
	2020		2019		2020		2019
United States	$	516,097	$	480,932	$	994,580	$	943,794
Europe	37,895		36,518		79,451		71,919
All other	8,444		16,683		23,131		26,606
Total revenues	$	562,436	$	534,133	$	1,097,162	$	1,042,319

Summary of Revenues from Customers Representing More Than 10% of Total Revenues

The following table presents a summary of the percentage of total revenues from customers that represented more than 10% of our total revenues: 

	Three Months Ended June 30,				Six Months Ended June 30,
	2020		2019		2020		2019
ESSDS	79	%	77	%	78	%	75	%
McKesson	10	%	12	%	11	%	15	%

Summary of a Reconciliation in Contract Liabilities from Contracts with Customer

The following table presents a reconciliation of our beginning and ending balances in contract liabilities from contracts with customers for the six months ended June 30, 2020 (in thousands): 

	Contract Liabilities
Balance as of December 31, 2019	$	9,581
Amount recognized within royalties and contract revenues	(2,360		)
Balance as of June 30, 2020	$	7,221